KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Change in Acquisitions & Divestments (2021 - 2026)

AbCellera Biologics filings provide 6 years of Change in Acquisitions & Divestments readings, the most recent being $143.8 million for Q1 2026.

  • Quarterly Change in Acquisitions & Divestments fell 24.33% to $143.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $459.8 million through Mar 2026, down 44.01% year-over-year, with the annual reading at $506.1 million for FY2025, 46.04% down from the prior year.
  • Change in Acquisitions & Divestments hit $143.8 million in Q1 2026 for AbCellera Biologics, up from $119.5 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $306.5 million in Q1 2024 and bottomed at $57.3 million in Q1 2022.
  • Average Change in Acquisitions & Divestments over 5 years is $177.0 million, with a median of $190.0 million recorded in 2025.
  • The largest annual shift saw Change in Acquisitions & Divestments surged 410.99% in 2022 before it tumbled 57.73% in 2025.
  • AbCellera Biologics' Change in Acquisitions & Divestments stood at $92.4 million in 2022, then surged by 190.09% to $268.0 million in 2023, then decreased by 24.67% to $201.9 million in 2024, then plummeted by 40.79% to $119.5 million in 2025, then rose by 20.3% to $143.8 million in 2026.
  • Per Business Quant, the three most recent readings for ABCL's Change in Acquisitions & Divestments are $143.8 million (Q1 2026), $119.5 million (Q4 2025), and $83.1 million (Q3 2025).